Announcements Trials

Browse Landscape

Phase

Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 22 Endometrial Neoplasms 3 Triple Negative Breast Neoplasms 2 Prostatic Neoplasms 2 Uterine Cervical Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Sexual Dysfunctions, Psychological 1 Ovarian Neoplasms 1 Neoplasms by Site 1 Neoplasms 1 Hereditary Sensory and Autonomic Neuropathies 1 Head and Neck Neoplasms 1 HR+/HER2- Breast Cancer 1 HER2-positive Breast Cancer 1 Fallopian Tube Neoplasms 1 Endometrioid Endometrial Cancer 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Intraductal, Noninfiltrating 1 Breast Neoplasms, Male 1 Breast Diseases 1 Breast Carcinoma In Situ 1 Anatomic Stage I Breast Cancer AJCC v8 1 Advanced Unresectable or Metastatic Breast Cancer of Adults 1 Advanced Solid Tumor 1

Interventions

Letrozole 1 Fulvestrant 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × HR+/HER2- Breast Cancer × Letrozole × Clear all

NCT06998407 2026-05-04

AVZO-023-1001

Avenzo Therapeutics, Inc.

Phase 1/2 Recruiting

HR+/HER2- Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡